Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dabrafenib”

138 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 138 results

Early research (Phase 1)Study completedNCT01582997
What this trial is testing

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT01153763
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 92
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Early research (Phase 1)Study completedNCT02110355
What this trial is testing

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Who this might be right for
Advanced MalignancyAdvanced Solid TumorsCancer+4 more
Kartos Therapeutics, Inc. 31
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Testing effectiveness (Phase 2)Looking for participantsNCT07110246
What this trial is testing

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Who this might be right for
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco 96
Testing effectiveness (Phase 2)Active Not RecruitingNCT03919071
What this trial is testing

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Who this might be right for
Anaplastic AstrocytomaAnaplastic Astrocytoma, Not Otherwise SpecifiedAnaplastic Ganglioglioma+5 more
National Cancer Institute (NCI) 58
Not applicableEnded earlyNCT05848219
What this trial is testing

Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Who this might be right for
Metastatic Melanoma
Novartis Pharmaceuticals 543
Testing effectiveness (Phase 2)Active Not RecruitingNCT01972347
What this trial is testing

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 35
Not applicableStudy completedNCT06337617
What this trial is testing

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Who this might be right for
BRAF V600 Mutation Positive Melanoma
Novartis Pharmaceuticals 90
Testing effectiveness (Phase 2)Study completedNCT01726738
What this trial is testing

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Who this might be right for
Stage III MelanomaStage IV MelanomaUnresectable Melanoma+1 more
UNC Lineberger Comprehensive Cancer Center 17
Not applicableNo Longer AvailableNCT04507919
What this trial is testing

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Carcinoma
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01340846
What this trial is testing

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 48
Large-scale testing (Phase 3)Study completedNCT01682083
What this trial is testing

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Who this might be right for
Melanoma
Novartis Pharmaceuticals 870
Early research (Phase 1)WithdrawnNCT02447939
What this trial is testing

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Testing effectiveness (Phase 2)Active Not RecruitingNCT04675710
What this trial is testing

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Who this might be right for
Thyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell Carcinoma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT04527549
What this trial is testing

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+2 more
ECOG-ACRIN Cancer Research Group 5
Testing effectiveness (Phase 2)Study completedNCT01682213
What this trial is testing

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 23
Testing effectiveness (Phase 2)UnknownNCT05876806
What this trial is testing

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Who this might be right for
Cancer
Se Jun Park 30
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Load More Results